Full Text View
Tabular View
No Study Results Posted
Related Studies
EARLY 3-Months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA
This study has been completed.
Study NCT00562588   Information provided by Boehringer Ingelheim Pharmaceuticals
First Received: July 6, 2007   Last Updated: March 5, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cerebrovascular Accident
Additional conditions recognized in this trial
Cerebral Infarction
Stroke
More general conditions related to this trial
Brain Diseases
Brain Infarction
Brain Ischemia
Cardiovascular Diseases
Central Nervous System Diseases
Cerebrovascular Disorders
Nervous System Diseases
Vascular Diseases
Interventions listed in this trial
ASA 100 mg qd
Additional drug interventions recognized in this trial
Dipyridamole
More general drug interventions related to this trial
Cardiovascular Agents
Enzyme Inhibitors
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Phosphodiesterase Inhibitors
Platelet Aggregation Inhibitors
Therapeutic Uses
Vasodilator Agents
Sponsors listed in this trial
Boehringer Ingelheim Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services